Answers are grounded in this paper and cite their sources.
Cardiovascular diseases are a leading cause of morbidity and mortality worldwide. Despite improvements in prevention and medical treatment that have increased life expectancy, the global burden of cardiovascular disease remains high.1,2 In particular, heart failure and ischaemic heart disease have increased significantly3,4 and are expected to rise further in the near future, driven in part by population ageing and persistent economic disparities. This growing challenge underscores the urgent need to strengthen cardiovascular prevention and to develop tailored strategies based on the socio-demographic index (SDI) of each region and the needs of specific populations. In this context, it is essential to acknowledge the existence of various cardiovascular risk prediction models, each with different abilities to stratify individuals into risk categories. As shown by Sud et al.,5 applying different models to the same population can lead to markedly different clinical decisions, particularly concerning medication prescriptions. For example, the SCORE2 model may more efficiently allocate statin therapy to higher-risk individuals, achieving a lower number needed to treat (NNT) but potentially preventing fewer total events at the population level. Conversely, models like the Framingham Risk Score may recommend treatment for broader, lower-risk populations, resulting in a higher NNT and a higher number of events prevented.
No takes yet. Share an insight, caveat, or question.
Disabato et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: